Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus
- PMID: 8675330
- PMCID: PMC174059
- DOI: 10.1128/iai.64.6.2220-2224.1996
Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus
Abstract
Vibrio vulnificus is an oyster-associated bacterial pathogen that causes life-threatening fulminating septicemia and necrotizing wound infections in humans. The capsular polysaccharide of V. vulnificus (VvPS) is critical for virulence. Previously we showed that active immunization of mice with a VvPS-tetanus toxoid (VvPS-TTa) conjugate vaccine conferred significantly higher protection against subsequent lethal challenge than immunization with VvPS alone. In the current study, we examined the utility of immunoprophylaxis or immunotherapy with hyperimmune antisera elicited by VvPS-TTa and VvPS-TTb conjugate vaccines prepared by different synthetic schemes. First we demonstrated that the Ribi adjuvant significantly enhanced the murine antibody response (P < or = 0.02) to both conjugates. Subsequently, high-titered polyclonal antisera were raised to VvPS-TTa and VvPS-TTb conjugate vaccines by using Ribi adjuvant or Freund's adjuvants. Antisera were observed to have protective effects when administered before and after acute lethal infection. All animals receiving prophylactic antisera intraperitoneally 24 h before lethal challenge with homologous carbotype 1 were protected, while 73 to 100% of control mice succumbed. Immunotherapy was also effective, with survival rates of 60 to 73% seen among mice when antisera were administered 2 h after bacterial challenge, at a time when symptoms of infection were already apparent. The protective effect of capsular antiserum appeared to be serotype specific. Antisera to the, carbotype 1 VvPS-TTa vaccine did not confer cross-protection against lethal challenge with carbotype 2 V. vulnificus despite partial structural similarity and a weak serological cross-reaction between the two carbotypes. Immune globulins induced by a potential multivalent VvPS conjugate vaccine composed of clinically prevalent carbotypes may have utility in the management of V. vulnificus infections and deserve further evaluation.
Similar articles
-
Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model.Infect Immun. 1995 Aug;63(8):2906-11. doi: 10.1128/iai.63.8.2906-2911.1995. Infect Immun. 1995. PMID: 7622211 Free PMC article.
-
Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.Infect Immun. 1994 Aug;62(8):3236-43. doi: 10.1128/iai.62.8.3236-3243.1994. Infect Immun. 1994. PMID: 8039893 Free PMC article.
-
Protection against Vibrio vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein.Vaccine. 2014 Jan 3;32(2):271-6. doi: 10.1016/j.vaccine.2013.11.019. Epub 2013 Nov 17. Vaccine. 2014. PMID: 24252692
-
Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.Pediatr Infect Dis J. 1998 Sep;17(9 Suppl):S117-22. doi: 10.1097/00006454-199809001-00005. Pediatr Infect Dis J. 1998. PMID: 9781743 Review.
-
Glycoconjugate vaccines and immune interference: A review.Vaccine. 2010 Aug 2;28(34):5513-23. doi: 10.1016/j.vaccine.2010.06.026. Epub 2010 Jun 25. Vaccine. 2010. PMID: 20600514 Review.
Cited by
-
Immune response and immunotherapy to Cryptococcus infections.Immunol Res. 2006;35(3):191-208. doi: 10.1385/IR:35:3:191. Immunol Res. 2006. PMID: 17172646 Review.
-
Differential expression of Vibrio vulnificus capsular polysaccharide.Infect Immun. 1999 May;67(5):2250-7. doi: 10.1128/IAI.67.5.2250-2257.1999. Infect Immun. 1999. PMID: 10225881 Free PMC article.
-
Total Synthesis of the Tetrasaccharide Haptens of Vibrio vulnificus MO6-24 and BO62316 and Immunological Evaluation of Their Protein Conjugates.JACS Au. 2021 Nov 9;2(1):97-108. doi: 10.1021/jacsau.1c00190. eCollection 2022 Jan 24. JACS Au. 2021. PMID: 35098226 Free PMC article.
-
Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms.Infect Immun. 2014 Nov;82(11):4813-23. doi: 10.1128/IAI.02130-14. Epub 2014 Aug 25. Infect Immun. 2014. PMID: 25156730 Free PMC article.
-
Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus.Infect Immun. 2001 Nov;69(11):6893-901. doi: 10.1128/IAI.69.11.6893-6901.2001. Infect Immun. 2001. PMID: 11598064 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources